Clinical Trial: Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases

Brief Summary: This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan may help to determine how fluorine F 18 clofarabine is distributed throughout the body.

Detailed Summary:

PRIMARY OBJECTIVES:

I. Determine how fluorine F 18 clofarabine (18F‐clofarabine) is distributed in the body, in patients with autoimmune and inflammatory diseases.

II. Determine whether 18F‐clofarabine can be used to image patients with autoimmune and inflammatory diseases.

OUTLINE:

Patients receive fluorine F 18 clofarabine intravenously (IV) and undergo a single PET/CT scan for up to 120 minutes.


Sponsor: Jonsson Comprehensive Cancer Center

Current Primary Outcome: Standardized Uptake Value [ Time Frame: Baseline up to 240 minutes after injection ]

Standardized Uptake Value (SUV) will be the primary unit for assessment. Using standard PET/CT viewing software, the SUV will be measured for different organs and lesions of suspected disease and compared to reference/background tissues.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Jonsson Comprehensive Cancer Center

Dates:
Date Received: September 8, 2016
Date Started: January 2016
Date Completion: August 2022
Last Updated: October 4, 2016
Last Verified: September 2016